Addressed Ongoing changes in health policy and reimbursement strategies for each EU member state, such as the challenge of fiscal forecasting and budgeting is even more difficult than country-by – country health systems develop their own reimbursement policies and rates.
1 Lok A et al. Quadruple therapy with BMS – 790052, BMS – 650032 and peg – IFNRBV for 24 weeks results in 100 percent SVR12 in HCV genotype 1 null responders. Abstract The International Liver CongressTM 2011 presents.. The current standard of care for HCV therapy is PegIFN – alpha plus RBV – a dual therapy. The addition of DAAs marks the next evolution step in the treatment – a triple therapy. However, the new data suggests that now that quadruple therapy could be the next generation of the treatment of chronic HCV patients. Heiner Wedemeyer, EASL Secretary General, said: Quadruple therapy is possibly the future of HCV treatment, this study is a way to confirm that anticipated that anticipated that the first DAAs and triple therapy is approved is approved this year this year will quadruple therapy to profound effect profound effect on the virological response, with less of a resistance problem . Continue reading “Addressed Ongoing changes in health policy and reimbursement strategies for each EU member state.”